Expertise

Our research focuses on identifying and characterizing host single nucleotide polymorphism (SNP) signatures that identify healthy men at risk of developing clinically aggressive lethal prostate cancer rather than the more common indolent phenotype with a particular focus on defining key pathogenic mechanisms that can explain the current increased incidence and mortality seen among African-American prostate cancer patients. In addition, we are examining the role of environmental toxic exposures in prostate cancer carcinogenesis by analyzing oxidative DNA damage in these same patient groups. In bladder cancer, we are developing new therapeutic protocols for patients of all disease stages with a translational focus on genetic and epigenetic signatures as a prognostic tool and as a potential targets for future drug development.

  • Genitourinary Cancer
  • Testis Cancer
  • Prostate Cancer

Dr. Hahn???s clinical and translational research interests focus on improving outcomes for patients with bladder and prostate cancer through: 1) The identification and validation of predictive biomarkers relevant to GU cancers, and 2) The identification of novel therapeutic and preventative targets for GU cancer patients.

Communities
Oncology
Degrees
MD, Indiana University, Indianapolis, 2000